DRUGMAKER AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corp., the companies said Monday. Through the tie-up, AstraZeneca aims to ride a wave of regulatory reform in China’s pharmaceuticals sector and get new drugs to the market more quickly. It dovetails with the government plan to see more “discovered-in-China” drugs as the country targets life sciences for growth. The FIIF’s remit in pharmaceuticals is to promote such local drug development and manufacturing. China is now the world’s second-largest drugs market after the United States, with more cases of cancer and diabetes than any other nation, creating a big opportunity for local and international drug companies. Recently, the China Food and Drug Administration has taken steps to accelerate new drug approvals, while local funding agencies are also moving faster to agree payments for innovative drugs, albeit with some tough negotiations on pricing. The reforms have triggered growing interest in China as a center for drug development, reflected in a wave of initial public offerings and licensing deals with foreign drug companies. In the case of the new joint venture, Dizal will incorporate all the scientific and technical capacity of AstraZeneca’s existing innovation center in Shanghai, including exclusive rights to three drugs in pre-clinical development. Dizal’s chief executive will be Zhang Xiaolin, previously head of the innovation center. In exchange for the AstraZeneca assets, FIIF will provide development funding and expertise in establishing strategic partnerships in China. There are no upfront payments. (SD-Agencies) |